Aplastic anemia

The FDA ( Food and Drug Administration ) has approved Adcetris ( Brentuximab vedotin ) for the treatment of patients...


The European Commission ( EC ) has approved Revolade ( Eltrombopag ) for the treatment of adult patients with severe...


Revolade ( Eltrombopag ) is used in adults for the treatment of: • long-term immune thrombocytopenic purpura ( ITP ), a...


Eltrombopag ( United States: Promacta; Europe: Revolade ), in addition to the approval for severe aplastic anemia in the U.S.,...


The Food and Drug Administration ( FDA ) has approved a supplemental New Drug Application ( sNDA ) for the...


Survival data from two Brentuximab vedotin ( Adcetris ) pivotal Phase 2 clinical trials in relapsed / refractory Hodgkin lymphoma...


Currently, there are no Factor X inhibitors approved for indication to reduce the risk of thrombotic cardiovascular events in patients...


A comparison clinical study of two aplastic anemia treatments found that Atgam ( lymphocyte immune globulin, anti-thymocyte globulin [equine] ),...